Article
Hematology
Yizhen Li, Xu Yang, Yu Sun, Zhenhua Li, Wenjian Yang, Bensheng Ju, John Easton, Deqing Pei, Cheng Cheng, Shawn Lee, Ching-Hon Pui, Jiyang Yu, Hongbo Chi, Jun J. Yang
Summary: T-cell immunity plays a pivotal role in maintaining long-term remission of acute lymphoblastic leukemia (ALL) and the interplay between host immunity and drug resistance can be harnessed to improve chemotherapy outcomes for ALL.
Article
Oncology
Charlotte E. J. Downes, Barbara J. McClure, John B. Bruning, Elyse Page, James Breen, Jacqueline Rehn, David T. Yeung, Deborah L. White
Summary: The study demonstrates that the JAK2 p.G993A mutation can confer resistance to multiple JAK inhibitors by modulating the mobility of the JAK2 activation loop, providing insights for future drug design and therapeutic strategies in high-risk patients with JAK2-rearranged B-cell acute lymphoblastic leukemia.
NPJ PRECISION ONCOLOGY
(2021)
Article
Hematology
Hagop Kantarjian, Nicholas J. Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fadi G. Haddad, Issa Khouri, Courtney D. DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero, Partow Kebriaei, Rebecca Garris, Sanam Loghavi, Jeffrey Jorgensen, Monica Kwari, Susan O'Brien, Farhad Ravandi, Elias Jabbour
Summary: The combination of ponatinib and hyper-CVAD chemotherapy showed high rates of complete molecular remissions and survival in patients with Philadelphia chromosome-positive acute lymphocytic leukemia. Further studies with a larger cohort and longer follow-up are needed to establish this regimen as a new standard of care.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Fadi G. G. Haddad, Koji Sasaki, Aram Bidikian, Ghayas C. C. Issa, Tapan Kadia, Nitin Jain, Yesid Alvarado, Nicholas J. J. Short, Naveen Pemmaraju, Sanam Loghavi, Keyur P. P. Patel, Rashmi Kanagal-Shamanna, Musa Yilmaz, Lucia Masarova, Elias Jabbour, Hagop Kantarjian
Summary: Patients with chronic myeloid leukemia (CML) and T315I mutation have a poor prognosis. The survival of CML patients in the post-ponatinib era is uncertain. This study found that CML-CP patients at the time of T315I mutation detection had better survival compared to those in AP or BP. Treatment with third-generation tyrosine kinase inhibitors seemed to improve survival in CML-CP patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Tingting Lu, Jiangyan Cao, Fengming Zou, Xixiang Li, Aoli Wang, Wenliang Wang, Huamin Liang, Qingwang Liu, Chen Hu, Cheng Chen, Zhenquan Hu, Wenchao Wang, Lili Li, Jian Ge, Yang Shen, Tao Ren, Jing Liu, Ruixiang Xia, Qingsong Liu
Summary: CHMFL-48 is a novel type II kinase inhibitor that potently inhibits the wild-type BCR-ABL kinase and a panel of imatinib-resistant mutants. This drug shows strong inhibitory activity in a cellular context, blocking autophosphorylation of BCR-ABL kinase, affecting downstream signaling mediators, and inducing cell cycle progression blockade and apoptosis.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Oncology
Yun Xu, Ziting Wang, Lei Zhang, Congying Gao, Fahui Li, Xueming Li, Yu Ke, Hong-Min Liu, Zhenbo Hu, Liuya Wei, Zhe-Sheng Chen
Summary: The compound JOA can inhibit the proliferation of chronic myeloid leukemia cells, including those with the BCR-ABL-T315I mutation, and induce cell differentiation. This effect may be mediated by the inhibition of the BCR-ABL/c-MYC signaling pathway. JOA shows potential as a lead compound for overcoming imatinib resistance in CML therapy.
Article
Biochemistry & Molecular Biology
Rachid Lahlil, Anne Aries, Maurice Scrofani, Celine Zanetti, Desline Hennequin, Bernard Drenou
Summary: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by the presence of the BCR-ABL fusion gene. Treatment with tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) has significantly improved clinical outcomes for CML patients, but IM resistance remains a major challenge. The cause of IM resistance in CML cells is unclear, but additional genetic alterations in leukemic stem cells (LSCs) are a common cause of relapse. A study found that a rare subpopulation of stem cells called very small embryonic-like stem cells (VSELs) in adult CML patients is resistant to IM and less sensitive to apoptosis compared to leukemic hematopoietic stem cells (HSCs). The expression levels of certain miRNAs are also affected in these IM-resistant VSELs, including miR-126 and miR-21, which are involved in LSC leukemia-initiating capacity and growth.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Annie Luong, Fabio Cerignoli, Yama Abassi, Nora Heisterkamp, Hisham Abdel-Azim
Summary: The study validates a novel application of the xCELLigence system as a continuous co-culture for assessing the long-term effects of drug treatment on BCP-ALL cells. The results demonstrate that impedance can be used as a new approach to monitor drug treatment and sensitivity of primary BCP-ALL cells in the presence of protective microenvironmental cells. Moreover, the system was able to discriminate sensitivity of different ALLs to targeted kinase inhibitors and showed differences in sensitivity of CRLF2-driven BCP-ALL cell lines to ruxolitinib.
Article
Hematology
Anjali S. Advani, Anna Moseley, Kristen M. O'Dwyer, Brent L. Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Summary: This study evaluated the feasibility and outcomes of the combination of blinatumomab, dasatinib, and steroids for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients. The results showed that this combination therapy was safe and effective, with a 3-year overall survival rate of 87% and a disease-free survival rate of 77%.
Article
Pharmacology & Pharmacy
Congying Gao, Lei Zhang, Yun Xu, Xiangyu Ma, Peilei Chen, Zhe-Sheng Chen, Liuya Wei
Summary: In this study, the potent histone deacetylase inhibitor I13 was assessed for its effect on chronic myeloid leukemia (CML) cells harboring T315I-mutated and wild-type BCR-ABL. I13 showed strong activity against both types of cells, inducing cell differentiation and suppressing proliferation by causing cell cycle G0/G1-phase accumulation. It was found that I13 blocked the CML signaling pathway by depleting BCR-ABL, resulting in cell differentiation. These findings highlight I13 as a BCR-ABL modulator for overcoming drug resistance caused by T315I-mutated BCR-ABL and have implications for CML therapy development.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Hematology
Simona Soverini, Margherita Martelli, Luana Bavaro, Caterina De Benedittis, Cristina Papayannidis, Chiara Sartor, Federica Sora, Francesco Albano, Sara Galimberti, Elisabetta Abruzzese, Mario Annunziata, Sabina Russo, Manuela Stulle, Annalisa Imovilli, Massimiliano Bonifacio, Elena Maino, Fabio Stagno, Claudia Maria Basilico, Erika Borlenghi, Claudio Fozza, Flavio Mignone, Roberta Minari, Stefania Stella, Michele Baccarani, Michele Cavo, Giovanni Martinelli
Summary: Our study compared the results of Sanger sequencing and next-generation sequencing in Ph+ ALL patients, revealing that NGS provides more accurate and sensitive detection of mutations, particularly in cases of hematologic resistance and minimal residual disease.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Lauren M. Brown, Soroor Hediyeh-Zadeh, Teresa Sadras, Hannah Huckstep, Jarrod J. Sandow, Ray C. Bartolo, Hansen J. Kosasih, Nadia M. Davidson, Breon Schmidt, Stefan Bjelosevic, Ricky Johnstone, Andrew Webb, Seong L. Khaw, Alicia Oshlack, Melissa J. Davis, Paul G. Ekert
Summary: This study identified a rare SFPQ-ABL1 fusion gene that plays a crucial role in cellular transformation in Ph-like ALL. Unlike other ABL1 fusion genes, SFPQ-ABL1 exhibits differences in subcellular localization, proliferative capacity, and activation of cellular pathways. These findings highlight the significance of fusion partners in mediating the function of ABL1 fusion genes.
Review
Hematology
Kai-Wen Tan, Yi-Yan Zhu, Qiao-Cheng Qiu, Man Wang, Hong-Jie Shen, Si-Man Huang, Han-Yu Cao, Chao-Ling Wan, Yan-Yan Li, Hai-Ping Dai, Sheng-Li Xue
Summary: Ph-like ALL is a high-risk subtype with a poor prognosis under conventional chemotherapy. It has a similar gene expression profile to Ph+ ALL but is highly heterogeneous in terms of genomic alterations. ABL class rearrangements are present in approximately 10-20% of Ph-like ALL cases. The efficacy of tyrosine kinase inhibitors for these fusion genes is still limited due to the heterogeneity and rarity of each fusion gene in clinical practice.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Zhen Liu, Wenlong Zheng, Yuan Liu, Binghe Zhou, Yuqing Zhang, Fan Wang
Summary: The study showed that HSPA8 is overexpressed in imatinib-resistant CML cells and its ablation can inhibit cell proliferation, induce autophagy, and enhance the anti-tumor activity of imatinib. These findings reveal the role of HSPA8 in IR-CML and suggest its potential as a target for treatment.
EXPERIMENTAL CELL RESEARCH
(2021)
Article
Hematology
Huimin Feng, Yue Fu, Zelong Cui, Minran Zhou, Lu Zhang, Zhenxing Gao, Sai Ma, Chunyan Chen
Summary: This study shows that PHF8 is significantly increased in CML patients and inhibits cell differentiation while promoting cell proliferation. Targeting PHF8, which directly regulates BCR::ABL1 expression, may be a useful therapeutic approach for CML.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Oncology
Riccardo Moia, Riccardo Dondolin, Maria Stefania De Propris, Donatella Talotta, Samir Mouhssine, Francesca Perutelli, Gianluigi Reda, Veronica Mattiello, Gian Matteo Rigolin, Marina Motta, Jacopo Olivieri, Renato Fanin, Omar Perbellini, Isacco Ferrarini, Francesca Romana Mauro, Ilaria Del Giudice, Luca Laurenti, Annamaria Tomasso, Massimo Gentile, Anna Maria Frustaci, Alessandra Tedeschi, Alessandro Gozzetti, Caterina Stelitano, Carlo Visco, Carol Moreno, Francesco Forconi, Roberto Marasca, Marta Coscia, Davide Rossi, Robin Foa, Gianluca Gaidano
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Michele Merli, Isacco Ferrarini, Francesco Merli, Alessandro Busca, Roberto Mina, Brunangelo Falini, Riccardo Bruna, Roberto Cairoli, Monia Marchetti, Alessandra Romano, Michele Cavo, Luca Arcaini, Livio Trentin, Chiara Cattaneo, Enrico Derenzini, Nicola Stefano Fracchiolla, Francesco Marchesi, Annamaria Scattolin, Atto Billio, Monica Bocchia, Massimo Massaia, Carlo Gambacorti-Passerini, Francesca Romana Mauro, Massimo Gentile, Sara Mohamed, Matteo Giovanni Della Porta, Elisa Coviello, Daniela Cilloni, Giuseppe Visani, Augusto Bramante Federici, Maria Chiara Tisi, Laura Cudillo, Sara Galimberti, Filippo Gherlinzoni, Livio Pagano, Anna Guidetti, Lorenza Bertu, Paolo Corradini, Francesco Passamonti, Carlo Visco
Summary: A study analyzed data from CLL patients with COVID-19 in Italy and found that male sex, age over 70, recent CLL treatment, and COVID-19 severity were independently associated with poor survival. The study revealed a dismal COVID-related outcome in a significant fraction of CLL patients.
HEMATOLOGICAL ONCOLOGY
(2023)
Letter
Oncology
Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, Gianni Binotto, Maria Cristina Miggiano, Elisabetta Calistri, Manuela Stulle, Anna Ermacora, Rossella Stella, Luigi Scaffidi, Fabio D'Amore, Giorgia Scotton, Davide Griguolo, Giovanna De Matteis, Roberta Bertorelle, Mauro Krampera, Gianpietro Semenzato, Renato Fanin, Daniela Damiani, Mario Tiribelli
Summary: In this study, we analyzed the expression of BCR::ABL1 in chronic myeloid leukemia patients who discontinued imatinib or 2nd generation tyrosine kinase inhibitors (2G-TKIs) while in sustained deep molecular response. The results showed that the levels of BCR::ABL1 were higher in patients who lost major molecular response after discontinuation, and this difference became more evident after 2 months.
Article
Hematology
Michelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, Antonella Vitale, Nicola Stefano Fracchiolla, Cristina Papayannidis, Fabio Giglio, Prassede Salutari, Ernesta Audisio, Barbara Scappini, Patrizia Zappasodi, Marzia Defina, Fabio Forghieri, Anna Maria Scattolin, Elisabetta Todisco, Monia Lunghi, Fabio Guolo, Maria Ilaria Del Principe, Mario Annunziata, Davide Lazzarotto, Michele Cedrone, Crescenza Pasciolla, Annalisa Imovilli, Ilaria Tanasi, Silvia Trappolini, Marco Cerrano, Roberta La Starza, Mauro Krampera, Nicola Di Renzo, Anna Candoni, Giovanni Pizzolo, Felicetto Ferrara, Robin Foa
Summary: This study analyzed the incidence, characteristics, treatment, and outcome of central nervous system (CNS) relapse in adult acute lymphoblastic leukemia (ALL) patients. The study found that 6.8% of patients experienced a CNS recurrence, with a higher incidence in T-cell ALL than in B-cell ALL. Risk factors for early CNS relapse included T-cell phenotype, hyperleucocytosis, and male gender. Treatment options varied, including chemotherapy, radiotherapy, intrathecal therapy, and novel agents. Allogenic transplant after complete remission showed a significant overall survival benefit. The time to CNS relapse was the strongest predictor of post-relapse survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Malgorzata Mikulska, Diletta Testi, Chiara Russo, Elisa Balletto, Chiara Sepulcri, Linda Bussini, Chiara Dentone, Federica Magne, Silvia Policarpo, Caterina Campoli, Filippo Miselli, Alessandro Cilli, Chiara Ghiggi, Sara Aquino, Carmen Di Grazia, Maddalena Giannella, Daniele Roberto Giacobbe, Antonio Vena, Anna Maria Raiola, Francesca Bonifazi, Pierluigi Zinzani, Michele Cavo, Roberto Lemoli, Emanuele Angelucci, Pierluigi Viale, Matteo Bassetti, Michele Bartoletti
Summary: The outcome of early treatment with antivirals or monoclonal antibodies for COVID-19 in patients with haematological malignancies is uncertain. A retrospective study was conducted to assess the efficacy of these treatments in mild/moderate cases between March 2021 and July 2022. Among the 328 patients included, treatment failure occurred in 9.5% of cases and was associated with older age, fewer vaccine doses, and monoclonal antibody therapy. The mortality rate in patients who developed severe COVID-19 despite early treatment was 26%.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Malgorzata M. M. Trawinska, Nicola Polverelli, Mario Tiribelli, Giulia Benevolo, Alessandra Iurlo, Alessia Tieghi, Florian H. H. Heidel, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Mattia Biondo, Marta Venturi, Luigi Scaffidi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Daniela Bartoletti, Simona Paglia, Nicola Vianelli, Michele Cavo, Massimiliano Bonifacio, Giuseppe A. A. Palumbo
Summary: This study explored the prognostic factors of cytopenic myelofibrosis (MF) and found that high molecular risk mutations, intermediate 2/high Dynamic International Prognostic Score System, and intermediate 2/high Myelofibrosis Secondary to Polycythemia Vera and Essential Thrombocythemia Prognostic Model were associated with cytopenic MF. Patients with cytopenia received lower doses of ruxolitinib and had worse treatment outcomes, suggesting the need for alternative therapeutic strategies.
Letter
Oncology
Francesca Palandri, Elena M. Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, Florian H. Heidel, Simona Paglia, Malgorzata M. Trawinska, Costanza Bosi, Elena Rossi, Mario Tiribelli, Alessia Tieghi, Alessandra Iurlo, Nicola Polverelli, Giovanni Caocci, Gianni Binotto, Francesco Cavazzini, Eloise Beggiato, Daniela Cilloni, Caterina Tatarelli, Francesco Mendicino, Maurizio Miglino, Monica Bocchia, Monica Crugnola, Camilla Mazzoni, Andrea D. Romagnoli, Giovanni Rindone, Sara Ceglie, Alessandra D'Addio, Eleonora Santoni, Daniele Cattaneo, Daniela Bartoletti, Roberto M. Lemoli, Mauro Krampera, Antonio Cuneo, Gianpietro C. Semenzato, Roberto Latagliata, Elisabetta Abruzzese, Nicola Vianelli, Michele Cavo, Alessandro Andriani, Valerio De Stefano, Giuseppe A. Palumbo, Massimo Breccia
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Katja Weisel, Meletios A. Dimopoulos, Jesus San-Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord-Bessen, Christine Yip, Mike Greenwood, Jackson Tang, Michele Cavo
Summary: Triplet regimens with immunomodulatory drugs and proteasome inhibitors have improved outcomes for patients with relapsed/refractory multiple myeloma. In the ELOQUENT-3 trial, the addition of elotuzumab to pomalidomide and dexamethasone did not impact the health-related quality of life (HRQoL) of patients. HRQoL remained stable and there were no significant differences between the treatment arms.
Article
Hematology
Darina Ocadlikova, Federico Lussana, Nicola Fracchiolla, Massimiliano Bonifacio, Lidia Santoro, Mario Delia, Sabina Chiaretti, Crescenza Pasciolla, Alessandro Cignetti, Fabio Forghieri, Francesco Grimaldi, Giulia Corradi, Letizia Zannoni, Stefania De Propris, Gian Maria Borleri, Ilaria Tanasi, Jayakumar Vadakekolathu, Sergio Rutella, Anna Rita Guarini, Robin Foa, Antonio Curti, Campus ALL
Summary: This study characterized the immune cell repertoire in the peripheral blood (PB) and bone marrow (BM) of B-cell precursor acute lymphoblastic leukaemia (B-ALL) patients treated with Blinatumomab. The results showed that Blinatumomab had different effects on PB and BM immune cell subsets, with transient changes in effector T-cell and Treg cell subsets in PB, and persistent increase in cytotoxic NK cells. Moreover, markers associated with T-cell-exhausted phenotype were modulated in BM T-cell subsets. These findings have important clinical implications in the therapeutic setting.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Gian Matteo Rigolin, Alice Traversa, Viviana Caputo, Ilaria Del Giudice, Antonella Bardi, Elena Saccenti, Sara Raponi, Caterina Ilari, Luciana Cafforio, Agnese Giovannetti, Antonio Pizzuti, Anna Guarini, Robin Foa, Antonio Cuneo
Summary: We investigated the relevance of genomic microarrays (GM) in refining prognosis in newly diagnosed low-risk chronic lymphocytic leukemia (CLL) patients. Additional lesions were detected by GM in 22.7% of patients compared to fluorescence in situ hybridization (FISH). GM and FISH showed a concordance rate of 87.4%. The presence of additional lesions by GM was associated with worse outcomes.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Eugenio Galli, Silvia Bellesi, Ilaria Pansini, Giacomo Di Cesare, Camilla Iacovelli, Rosalia Malafronte, Elena Maiolo, Patrizia Chiusolo, Simona Sica, Federica Sora, Stefan Hohaus
Summary: CD4+ and CD8+ chimeric antigen receptor T cells (CAR-T) play different roles in the in vivo anti-tumour response, and the CD4+/CD8+ ratio may impact CAR-T efficacy.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Giovanni Caocci, Massimiliano Bonifacio, Andrea Patriarca, Isabella Capodanno, Maria Cristina Miggiano, Mario Tiribelli, Massimo Breccia, Luigia Luciano, Valentina Giai, Alessandra Iurlo, Elisabetta Abruzzese, Carmen Fava, Shira Dinner, Jessica K. Altman, Gianantonio Rosti, Jorge Cortes, Marco Vignetti, David Cella
Summary: Patient-reported symptom monitoring from the beginning of therapy in patients with CML may be critical to improve adherence to therapy and early molecular response rates. The current findings suggest that systematic monitoring of patient-reported symptoms is associated with high adherence rates.
Article
Hematology
Gabriella Chirumbolo, Michele Dicataldo, Martina Barone, Gianluca Storci, Serena De Matteis, Noemi Laprovitera, Barbara Sinigaglia, Francesco Barbato, Enrico Maffini, Michele Cavo, Francesca Bonifazi, Mario Arpinati
Summary: Chronic GVHD (cGVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (HSCT) with no consistent biomarkers to predict its occurrence. This study aimed to evaluate the potential of antigen-presenting cell subsets and serum chemokine concentrations as biomarkers for cGVHD.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michele Cavo, Philippe Moreau, Meletios Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie-Laure Risse, Joseph Mikhael
Summary: The role, timing, and impact of transplantation on further therapy after relapse in multiple myeloma (MM) are still being debated in the era of highly active novel agents. The impact of prior transplantation on treatment benefit from monoclonal antibodies in patients with relapsed/refractory MM (RRMM) is largely unknown. This subgroup analysis examined efficacy and safety in patients from the Phase 3 IKEMA study with and without previous transplantation.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Bruno Paiva, Irene Manrique, Meletios A. Dimopoulos, Francesca Gay, Chang-Ki Min, Sonja Zweegman, Raphael Teipel, Maria -Victoria Mateos, Nicola Giuliani, Michele Cavo, Christine Rojas Hopkins, Weijun Fu, Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash, Ivan Spicka
Summary: Measurable residual disease (MRD) evaluation is helpful in determining treatment duration in multiple myeloma (MM). However, limited longitudinal data exists on MRD during maintenance. This study investigated the prognostic value of MRD dynamics and found that MRD status at randomization and MRD dynamics during maintenance impact progression-free survival (PFS) risk. These findings support the significance of MRD assessment during maintenance in MM.